| Subgroup               | Number of mutations | HR (95%CI) |
|------------------------|---------------------|------------|
|                        | <3  | ≥3     |          |
| All Patients           | 46  | 95     | 0.7 (0.4 to 1.2) |
| Age                    |     |        |          |
| ≥70                    | 39  | 33     | 1.4 (0.7 to 3.1) |
| <70                    | 40  | 29     | 2.0 (1.0 to 4.0) |
| ≥60                    | 14  | 10     | 1.7 (0.5 to 5.5) |
| <60                    | 65  | 52     | 1.8 (1.0 to 3.2) |
| Sex                    |     |        |          |
| Female                 | 40  | 20     | 1.4 (0.7 to 3.1) |
| Male                   | 39  | 42     | 2.0 (1.0 to 4.0) |
| Therapy                |     |        |          |
| Resection              | 22  | 31     | 2.0 (0.8 to 5.2) |
| Chemotherapy           | 50  | 25     | 1.2 (0.6 to 2.4) |
| FOLFIRINOX therapy     | 14  | 6      | 1.8 (0.6 to 5.3) |
| Location               |     |        |          |
| Pancreas head          | 51  | 34     | 1.5 (0.8 to 2.7) |
| Pancreas body and tail | 28  | 28     | 2.5 (1.0 to 6.3) |
| Tumor size             |     |        |          |
| >20mm                  | 69  | 44     | 1.8 (1.0 to 3.0) |
| ≤20mm                  | 10  | 18     | 4.1 (0.5 to 32.9) |
| Stage                  |     |        |          |
| IV                     | 46  | 12     | 0.9 (0.5 to 1.8) |
| I-III                  | 33  | 50     | 2.4 (1.1 to 5.3) |
| III-IV                 | 52  | 23     | 1.7 (0.9 to 3.3) |
| I-II                   | 27  | 39     | 1.9 (0.8 to 4.6) |

Worse prognosis in the number of mutations <3.